PurFECT: PURified Fatty acids for Endometriosis Clinical Trial
Research type
Research Study
Full title
PurFECT: PURified Fatty acids for Endometriosis Clinical Trial
IRAS ID
150575
Contact name
Andrew Horne
Contact email
Sponsor organisation
University of Edinburgh
Eudract number
2013-004938-15
Clinicaltrials.gov Identifier
14/SS/0012, REC
Research summary
Endometriosis (womb lining outside the womb) affects 6-10% of women and is associated with debilitating chronic pelvic pain. It costs the UK >£2.8 billion per year in loss of productivity. Endometriosis is managed surgically or medically. However, ~75% symptoms recur after surgery and available medical treatments (‘anti-hormones’) have undesirable side effects and are contraceptive. Omega-3 purified fatty acids (PUFA) have been shown in animal models to reduce factors that are thought to lead to endometriosis-associated pain, have minimal side effects and no effects on fertility. We plan to perform a pilot study to inform planning of a future multicentre trial to evaluate the efficacy of PUFA in the management of endometriosis-associated pain.
REC name
Scotland A REC
REC reference
14/SS/0012
Date of REC Opinion
29 May 2014
REC opinion
Further Information Favourable Opinion